Deltagen has industrialized a revolutionary in vivo technology
platform for the large-scale generation of functional information
on genes related to key areas of drug discovery.
Using a
preferred, targeted mutagenesis process, our scientists can delete—or
“knock out”—precise genes in mouse models and then
utilize an extensive phenotypic analysis program to determine the
specific function and potential pharmaceutical relevance of these
genes and the proteins they encode. The data are consolidated in DeltaBase®,
Deltagen’s premier in vivo mammalian gene function database.
The proprietary technology platform has been validated through collaborations
with some of the world’s leading pharmaceutical companies, including
Pfizer Inc., GlaxoSmithKline plc, and Merck & Co., Inc., as well
as with internationally recognized research institutions such as Stanford
University.
